ArticleScientific reports2026
Transcriptional profiling of the tumor microenvironment of recurrent and non-recurrent stage II colon cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Predicting recurrences in patients with stage II colon cancer remains a clinical challenge. This study aimed to uncover connections between gene expression, clinicopathological characteristics, and recurrence in patients with stage II colon cancer. Gene expression profiling was conducted on primary tumors from 94 well-characterized patients with stage II colon cancer using the PanCancer IO 360™ panel from NanoString Technologies, which includes 770 mRNAs related to tumor progression and the tumor microenvironment. Unsupervised hierarchical clustering, differential gene expression (DEG) and survival analyses were used to describe the relationship between gene expression, clinicopathological characteristics, and recurrence. Unsupervised hierarchical clustering revealed distinct gene expression patterns in pT4 tumors, particularly in pathways involving immune cell localization and myeloid cell activity. DEG analysis identified 156 differentially expressed genes in pT4 versus pT3 tumors, including the important chemokines, CCL2 and CXCL8, and the cytokine LIF. In addition, 35 upregulated genes associated with migration and extracellular processes were identified in patients with recurrence. Finally, SLC2A1 and VEGFA emerged as independent prognostic markers for time to recurrence and overall survival. In conclusion, this study unveiled distinct gene expression patterns in advanced pT4 tumors, and identified independent prognostic biomarkers that may prove useful in stage II colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.